Asunto(s)
Infecciones por Adenoviridae , Adenoviridae/inmunología , Traslado Adoptivo , Trasplante de Células Madre Hematopoyéticas , Linfocitos T , alfa-Manosidosis , Infecciones por Adenoviridae/inmunología , Infecciones por Adenoviridae/terapia , Aloinjertos , Humanos , Lactante , Masculino , Linfocitos T/inmunología , Linfocitos T/trasplante , alfa-Manosidosis/inmunología , alfa-Manosidosis/terapiaRESUMEN
Human adenovirus (ADV) infections are the cause of severe morbidity and mortality in transplant recipients. Cidofovir (CDV) is the current standard antiviral treatment. We report the case of a 3-year-old boy after lung transplantation with severe ADV sepsis, who was monitored for ADV-specific T cells during his disease and recovery. A strong increase in ADV-specific T cells was accompanied by resolution of ADV in blood and bronchoalveolar lavage fluid. Antiviral treatment with CDV was individually adapted according to anti-ADV immune responses, which provides a new method for tailoring antiviral treatment in lung transplant recipients.
Asunto(s)
Adenoviridae/aislamiento & purificación , Infecciones por Adenovirus Humanos/tratamiento farmacológico , Antivirales/uso terapéutico , Citosina/análogos & derivados , Trasplante de Pulmón/efectos adversos , Monitoreo Fisiológico/métodos , Organofosfonatos/uso terapéutico , Neumonía Viral/tratamiento farmacológico , Linfocitos T/virología , Infecciones por Adenovirus Humanos/diagnóstico , Infecciones por Adenovirus Humanos/virología , Antivirales/administración & dosificación , Líquido del Lavado Bronquioalveolar/virología , Preescolar , Cidofovir , Citosina/administración & dosificación , Citosina/uso terapéutico , Ensayo de Immunospot Ligado a Enzimas , Estudios de Factibilidad , Citometría de Flujo , Humanos , Huésped Inmunocomprometido , Terapia de Inmunosupresión/efectos adversos , Masculino , Organofosfonatos/administración & dosificación , Neumonía Viral/diagnóstico , Neumonía Viral/virología , Reacción en Cadena en Tiempo Real de la Polimerasa , Linfocitos T/inmunología , Carga ViralRESUMEN
Recently, germline mutations of DICER1 have been identified in patients with rare neoplasms suggesting the existence of a newly discovered cancer prone syndrome. Initially, DICER1 mutations were identified in patients with familial pleuropulmonary blastoma. Subsequently, additional manifestations of the syndrome have been identified including cystic nephroma, medulloepithelioma, Sertoli-Leydig cell tumor and others. The DICER1 gene encodes an enzyme that is involved in the biogenesis of microRNAs. The entire tumor spectrum and the respective tumor risks are unknown. We are in the process of launching a natural history study aimed at identifying more information on this new cancer syndrome.
